Stockreport

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and ...

Krystal Biotech, Inc.  (KRYS) 
Last krystal biotech, inc. earnings: 11/4 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.krystalbio.com/investors
PDF Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cys [Read more]